Prevalence of Alzheimer’s disease: Research and more

What Does Alzheimer’s Disease Prevalence Mean?

Prevalence describes how many people in a population are living with a condition at a particular time. It may be expressed as a total number, a percentage, or a rate per 100,000 people. Think of prevalence as a group photograph: everyone currently living with the condition is included.

Prevalence Is Not the Same as Incidence

Incidence counts new cases that develop during a defined period, usually one year. If prevalence is the group photo, incidence is the list of people who entered the room since January. Both measures are important. Prevalence helps communities plan clinics, long-term care, caregiver support, and health spending, while incidence helps researchers evaluate whether the risk of developing disease is rising or falling.

Alzheimer’s Disease and Dementia Are Not Identical Terms

Dementia is an umbrella term for declines in memory, language, reasoning, and other cognitive abilities that interfere with everyday life. Alzheimer’s disease is a specific progressive brain disease and the most common cause of dementia, accounting for an estimated 60% to 80% of dementia cases. Other causes include vascular dementia, Lewy body dementia, frontotemporal dementia, and mixed disease involving more than one form of brain pathology.

This distinction matters because some studies count Alzheimer’s dementia specifically, whereas others report all Alzheimer’s disease and related dementias, often shortened to ADRD. Comparing those estimates without reading the label is like comparing apples with an entire produce aisle.

How Common Is Alzheimer’s Disease in the United States?

The Alzheimer’s Association’s 2026 estimate indicates that approximately 7.4 million Americans age 65 and older have clinical Alzheimer’s dementia. About 74% are at least 75 years old. The estimated prevalence rises from 5.2% among adults ages 65 to 74 to 35.8% among people age 85 and older. In other words, slightly more than one in three members of the oldest age group is estimated to be affected.

People younger than 65 can also develop dementia. Current U.S. research on younger-onset disease remains limited, but approximately 200,000 Americans ages 30 to 64 may have younger-onset dementia. This category includes Alzheimer’s disease as well as other causes, so it should not be interpreted as a precise count of younger-onset Alzheimer’s alone.

Why Some Sources Report Lower Numbers

Readers may still encounter an estimate of 6.7 million or “more than 6 million” Americans with Alzheimer’s. Those figures often come from earlier publication years, older population projections, or different case definitions. A 2025 analysis estimated 7.2 million Americans age 65 and older were living with Alzheimer’s dementia, while the updated 2026 estimate increased to 7.4 million.

The difference is not evidence that millions of people suddenly developed Alzheimer’s overnight. Estimates change as the population ages, demographic projections are updated, and researchers refine their methods. The calendar moved forward, the data improved, and unfortunately the disease did not take the year off.

How Researchers Estimate Alzheimer’s Prevalence

Counting people with Alzheimer’s is more complicated than counting positive laboratory tests for an infection. Symptoms develop gradually, many people are never formally diagnosed, and Alzheimer’s-related brain changes may begin years before daily functioning is noticeably impaired.

Community-Based Clinical Studies

The leading 2026 estimate uses findings from the Chicago Health and Aging Project, a longitudinal community study in which participants received repeated cognitive evaluations. Researchers combined the study’s age-specific prevalence rates with updated U.S. Census population projections. This approach can identify people who meet clinical criteria even when their medical records contain no diagnosis. Its limitation is that a study based in one geographic area may not perfectly represent every U.S. community.

Medical Claims and Electronic Health Records

Medicare claims and electronic records cover enormous populations, making them useful for tracking diagnosed disease. However, they count only people who interacted with the health system and received a diagnosis code. A 2025 review of Medicare data suggested that about 9% of beneficiaries, or roughly 5.3 million people, may have Alzheimer’s disease or a related dementia. That is a valuable measure of documented disease, but it is not necessarily the full population prevalence.

Surveys and Self-Reported Diagnoses

National surveys may ask whether a doctor has ever told respondents that they have dementia. In a 2022 survey, 4% of U.S. adults age 65 and older reported a dementia diagnosis. The percentage increased from 1.7% among those ages 65 to 74 to 13.1% among adults age 85 and older. Self-reported surveys tend to produce lower estimates because some people have not been evaluated, do not remember the diagnosis, or rely on a family member to answer.

Biomarker-Based Estimates

Modern research can identify Alzheimer’s-related amyloid and tau changes through brain imaging, cerebrospinal fluid, and increasingly blood tests. Biomarkers may reveal biological Alzheimer’s disease before dementia is present. Consequently, estimates of biomarker-positive disease can be much larger than estimates of symptomatic Alzheimer’s dementia. Researchers must state clearly whether they are counting brain pathology, mild cognitive impairment, or dementia that interferes with everyday activities.

Underdiagnosis Makes the True Burden Harder to See

Population studies consistently suggest that many people who meet clinical criteria for dementia have not received a formal diagnosis. Even among Medicare beneficiaries with a diagnosis in their billing records, only about half report that they were told about it. Delayed recognition can limit access to treatment, safety planning, caregiver education, clinical trials, and financial or legal preparation.

Subjective cognitive decline offers another clue. During 2015–2020, approximately 10% of U.S. adults age 45 and older reported worsening confusion or memory loss, yet fewer than half had discussed those concerns with a healthcare professional. Subjective decline does not automatically mean Alzheimer’s diseasesleep problems, depression, medication effects, thyroid disorders, vitamin deficiencies, and other conditions can affect cognitionbut it deserves an appropriate medical conversation.

Which Groups Are Most Affected?

Age Remains the Strongest Known Risk Factor

Alzheimer’s disease is not a normal or inevitable part of aging, but advancing age is its greatest known risk factor. The steep increase in prevalence after age 85 explains why relatively small demographic changes in the oldest population can produce large changes in the national caseload.

Women Represent Nearly Two-Thirds of Cases

Of the estimated 7.4 million Americans age 65 and older with clinical Alzheimer’s dementia, approximately 4.5 million are women and 2.9 million are men. Women live longer on average, giving them more years in which the disease can develop. Current evidence does not establish that women at every age necessarily develop Alzheimer’s at a dramatically higher rate than men of the same age. Biology, survival patterns, education, cardiovascular health, and social conditions may all contribute.

Racial and Ethnic Disparities Are Significant

Many prevalence studies find that older Black Americans are about twice as likely to have Alzheimer’s or another dementia as older White Americans. Hispanic older adults may be approximately one and a half times as likely, although results vary among studies and between diverse Hispanic communities.

These differences should not be reduced to race as a biological explanation. Lifelong disparities in educational opportunity, income, healthcare access, neighborhood conditions, pollution exposure, cardiovascular disease, discrimination, and diagnostic services can influence brain health. Research has also found that Black study participants may be less likely than White participants to receive an Alzheimer’s or related dementia diagnosis despite cognitive findings.

Geography Shapes Prevalence and Access

County-level research has identified some of the highest estimated prevalence rates in eastern and southeastern communities. These patterns may reflect population age, racial and ethnic composition, cardiovascular risk factors, poverty, healthcare availability, and other local conditions. Geographic data help public-health agencies decide where memory clinics, caregiver programs, transportation services, and culturally appropriate outreach are most urgently needed.

Why Alzheimer’s Prevalence Is Expected to Rise

The U.S. population age 65 and older reached 55.8 million in 2020 after growing 38.6% in only a decade. By 2060, nearly one in four Americans is projected to be an older adult, and the population age 85 and older is expected to expand particularly rapidly.

Assuming no major prevention or treatment breakthrough, the number of Americans age 65 and older with clinical Alzheimer’s dementia is projected to reach 13.8 million by 2060. Approximately 6.7 million could be at least 85 years old, meaning the oldest adults may account for nearly half of all older Americans living with the condition.

A separate NIH-supported study examining dementia more broadly projected that annual new U.S. cases could rise from about 514,000 in 2020 to approximately one million in 2060. The projected increase is driven largely by population aging rather than proof that every individual’s personal risk is doubling.

The Burden Extends Far Beyond a Headcount

Alzheimer’s prevalence affects hospitals, long-term care facilities, home health services, employers, and millions of households. In 2022, Alzheimer’s disease or another dementia affected about 41% of nursing home residents, 44% of residential care residents, and 40% of hospice patients. These figures demonstrate how heavily dementia shapes the U.S. care system.

More than 12 million Americans provide unpaid care to someone with Alzheimer’s or another dementia. In 2025, approximately 12.7 million unpaid caregivers delivered an estimated 19.6 billion hours of assistancenearly 30 hours per caregiver each week on average. That work can include managing medications, preparing meals, arranging appointments, helping with bathing, preventing wandering, and answering the same question with fresh patience for the ninth time before lunch.

Healthcare and long-term care spending for people with Alzheimer’s and other dementias is projected to reach $409 billion in 2026, excluding the value of unpaid family care. Medicare and Medicaid are expected to cover almost two-thirds of that amount. Without major breakthroughs, annual costs could approach $1 trillion by mid-century in inflation-adjusted dollars.

What Current Alzheimer’s Research May Change

Blood Tests Could Improve Access to Diagnosis

In May 2025, the U.S. Food and Drug Administration cleared the first blood test designed to aid in detecting amyloid plaques associated with Alzheimer’s disease in symptomatic adults. The test measures a ratio involving phosphorylated tau and amyloid-beta. It does not replace a complete clinical evaluation, but it may reduce dependence on costly PET scans or invasive spinal-fluid testing.

More accessible biomarkers could reveal disease earlier and produce more biologically precise prevalence estimates. They could also create new challenges: health systems will need clear standards for deciding who should be tested, how results should be communicated, and how to prevent unequal access from widening existing disparities.

Researchers Are Studying Modifiable Risks

Age, family history, and genetics cannot be changed, but several factors associated with dementia risk can be addressed. Evidence supports attention to blood pressure, diabetes, cholesterol, physical activity, smoking, hearing loss, depression, obesity, social isolation, excessive alcohol use, head injury, and access to education and preventive care. These factors do not guarantee or completely prevent Alzheimer’s, but improving them may support cognitive health and reduce population-level risk.

More Representative Research Is Essential

Better prevalence estimates require studies that include people from different racial, ethnic, geographic, socioeconomic, linguistic, and cultural backgrounds. Researchers also need to include rural residents, adults with multiple chronic conditions, and people who historically have had limited access to specialty clinics. A national average can be useful, but it becomes far more useful when communities can see themselves in the data.

What the Statistics Feel Like in Everyday Life

The following experiences are composite examples created from common themes in dementia research and caregiving. They do not describe identifiable individuals.

The Daughter Who Becomes a Care Coordinator

At first, Elena notices ordinary-looking mistakes. Her mother pays the electric bill twice, loses her reading glasses, and repeats a story about the neighbor’s dog. Everyone jokes about getting older. Then Elena discovers unopened medication bottles and a scorched saucepan hidden beneath the sink. The family schedules an appointment, but the first available specialist visit is months away.

After the diagnosis, Elena gains a new unpaid position: appointment scheduler, medication manager, insurance translator, grocery shopper, transportation coordinator, and emergency contact. She still has her regular job, children, mortgage, and a phone that now seems permanently set to ring. National caregiver statistics suddenly stop feeling like statistics. They feel like Tuesday.

The Rural Couple Facing a Long Drive

Robert and James live in a small community where the nearest memory clinic is more than two hours away. Robert has begun getting lost on familiar roads, but he dislikes discussing it. James quietly takes over driving and labels kitchen drawers. He worries that seeking help will automatically mean losing independence.

The primary care office can perform an initial cognitive evaluation, but advanced imaging and specialist services require travel, time off work, and money for fuel and lodging. Their experience illustrates why diagnosis rates cannot be separated from access. A person may have the same symptoms in a large city and a rural county, yet travel through a very different healthcare maze.

The Worker With Younger-Onset Disease

Marcus is 57 when he begins struggling with tasks he has handled for decades. He misses deadlines, loses track of conversations, and receives a poor performance review. Because of his age, colleagues assume he is distracted or burned out. Even Marcus initially blames stress.

Testing eventually reveals younger-onset Alzheimer’s disease. The diagnosis affects far more than memory. Marcus must consider workplace accommodations, disability benefits, retirement savings, health insurance, and how to explain the condition to teenage children. Services designed mainly for retirees do not always fit a family still paying tuition and planning a career. His experience shows why younger-onset cases, though much less common, require specialized research and support.

The Family That Waited Too Long to Ask

Mrs. Carter’s relatives notice memory changes but hesitate to raise the subject. They fear embarrassing her and remember relatives who received poor treatment from healthcare institutions. At appointments, short visit times leave little room for sensitive discussion. Her daughter finally brings written examples of missed meals, confusion about money, and nighttime wandering.

The evaluation produces both grief and relief. The family cannot reverse what has happened, but it can create a safety plan, review medications, establish legal documents, and connect with support services. An earlier diagnosis would not have made the situation easy. It might, however, have made the difficult parts less chaotic.

These composite stories explain why Alzheimer’s prevalence is not merely a chart about older adults. Each case changes the routines of spouses, children, coworkers, clinicians, and communities. Behind every national estimate are people improvising solutions at kitchen tables, learning unfamiliar medical language, and discovering that caregiving contains equal portions of love, fatigue, humor, and paperwork.

Conclusion

The prevalence of Alzheimer’s disease in the United States is substantial and rising. The best current estimate places the number of adults age 65 and older living with clinical Alzheimer’s dementia at 7.4 million in 2026, with age remaining the most powerful driver of risk. Women represent most existing cases, and Black and Hispanic communities frequently experience a disproportionate burden shaped by health, economic, environmental, and healthcare inequalities.

Prevalence estimates will continue to evolve as researchers improve population studies, expand representation, and incorporate blood and imaging biomarkers. Better counting will not solve Alzheimer’s by itself, but it can reveal unmet needs, guide resources, improve diagnosis, and help the healthcare system prepare. Statistics may be terrible dinner companions, but they are excellent planning toolsand the United States has a great deal of planning to do.